Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients

NCT03184467 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease

Interventions

DRUG: Normal Saline 0.9%
DRUG: GV1001 0.56 mg
DRUG: GV1001 1.12 mg

Sponsor

GemVax & Kael